In this context, we developed an immunocompetent murine BLCA model to study the effects of IFNα on cancer cells and the TME using a novel murine equivalent of Nadofaragene (muAd-Ifnα). This evidence concerns the gene IFNA1 and bladder transitional cell carcinoma.